Pfizer entered a research collaboration and licensing agreement with Enodia Therapeutics to discover Sec61 inhibitor candidates. Enodia will run discovery to screen, optimize, and develop small-molecule Sec61 inhibitors across collaboration targets, while Pfizer will handle clinical, manufacturing, regulatory, and commercial activities after the collaboration period. The deal includes an undisclosed upfront payment and eligibility for research, development, and sales milestones, with total potential value estimated above $500 million. Enodia said it would receive non-dilutive capital alongside milestone-driven upside. For platform-focused biotech, the agreement highlights pharma’s continued appetite for next-generation protein biogenesis modulation strategies that aim to preserve essential cellular functions while disabling disease-driving proteins.